JP2022553351A5 - - Google Patents

Info

Publication number
JP2022553351A5
JP2022553351A5 JP2022523718A JP2022523718A JP2022553351A5 JP 2022553351 A5 JP2022553351 A5 JP 2022553351A5 JP 2022523718 A JP2022523718 A JP 2022523718A JP 2022523718 A JP2022523718 A JP 2022523718A JP 2022553351 A5 JP2022553351 A5 JP 2022553351A5
Authority
JP
Japan
Prior art keywords
amino
carboxamide
chlorophenyl
alkyl
hydroxyethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022523718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553351A (ja
JP7738550B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/056936 external-priority patent/WO2021086726A1/en
Publication of JP2022553351A publication Critical patent/JP2022553351A/ja
Publication of JP2022553351A5 publication Critical patent/JP2022553351A5/ja
Application granted granted Critical
Publication of JP7738550B2 publication Critical patent/JP7738550B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022523718A 2019-10-28 2020-10-22 Ｅｒｋ１およびｅｒｋ２の複素環式阻害剤の使用のための改善された方法、キット、組成物、ならびに投与レジメン Active JP7738550B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962926869P 2019-10-28 2019-10-28
US62/926,869 2019-10-28
PCT/US2020/056936 WO2021086726A1 (en) 2019-10-28 2020-10-22 Improved methods, kits, compositions and dosing regimens for the use of heterocyclic inhibitors of erk1 and erk2

Publications (3)

Publication Number Publication Date
JP2022553351A JP2022553351A (ja) 2022-12-22
JP2022553351A5 true JP2022553351A5 (https=) 2023-10-27
JP7738550B2 JP7738550B2 (ja) 2025-09-12

Family

ID=73476229

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022523718A Active JP7738550B2 (ja) 2019-10-28 2020-10-22 Ｅｒｋ１およびｅｒｋ２の複素環式阻害剤の使用のための改善された方法、キット、組成物、ならびに投与レジメン

Country Status (9)

Country Link
US (1) US20230027072A1 (https=)
EP (1) EP4051264A1 (https=)
JP (1) JP7738550B2 (https=)
KR (1) KR20220106754A (https=)
CN (2) CN120204227A (https=)
AU (1) AU2020375720A1 (https=)
CA (1) CA3158910A1 (https=)
TW (1) TW202128665A (https=)
WO (1) WO2021086726A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017026159A2 (pt) 2015-06-15 2018-08-14 Asana Biosciences, Llc inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer
US11866421B2 (en) * 2021-05-31 2024-01-09 Epigen Biosciences, Inc. Pyrimidine and pyridine amine compounds and usage thereof in disease treatment
JP2024526135A (ja) * 2021-06-24 2024-07-17 エラスカ，インク． Ｅｒｋ１／２阻害剤とｋｒａｓ ｇ１２ｃ阻害剤の併用療法
WO2022271939A1 (en) * 2021-06-24 2022-12-29 Erasca, Inc. Erk1/2 and cdk4/6 inhibitors combination therapy
US20240285624A1 (en) * 2021-06-24 2024-08-29 Erasca, Inc. Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy
CN117957001A (zh) * 2021-06-24 2024-04-30 阿沙纳生物科学公司 Erk1/2抑制剂组合疗法
AU2022299193A1 (en) * 2021-06-24 2024-01-04 Erasca, Inc. Erk1/2 and egfr inhibitors combination therapy
IL309401A (en) * 2021-06-24 2024-02-01 Erasca Inc Combined treatment with ERK1/2 and SHP2 inhibitors
WO2023044065A1 (en) * 2021-09-17 2023-03-23 Erasca, Inc. Jak inhibitor with erk1/2 and/or shp2 inhibitors combination therapy
WO2024064690A1 (en) * 2022-09-20 2024-03-28 Erasca, Inc. Erk1/2 inhibitor polymorph forms

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743941B2 (en) 2001-06-15 2004-06-01 Aventis Pharma Deutschland Gmbh Process for the production of piperidine derivatives
CA2547080A1 (en) * 2003-12-02 2005-07-28 Vertex Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors and uses thereof
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
EA024729B1 (ru) * 2009-11-13 2016-10-31 Джиноско Киназные ингибиторы
BR112017026159A2 (pt) * 2015-06-15 2018-08-14 Asana Biosciences, Llc inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer

Similar Documents

Publication Publication Date Title
JP2022553351A5 (https=)
RU2017139727A (ru) Гетероциклические ингибиторы erk1 и erk2 и их применение для лечения злокачественного новообразования
RU2323215C2 (ru) Замещенные производные хиназолина как ингибиторы ауроракиназы
JP2021011495A5 (https=)
RU2013133800A (ru) Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
JP2023524598A5 (https=)
JP2005526723A5 (https=)
JP2007519754A5 (https=)
RU2019136279A (ru) C5 -Анилинохиназолиновые соединения и их использование в лечении рака
JP2022554169A5 (https=)
JP2008516974A5 (https=)
RU2005137403A (ru) Новые замещенные 3-сера-индолы
JP2002536445A5 (https=)
HRP20141094T1 (hr) 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze
JP2009542723A5 (https=)
RU2011127232A (ru) Апоптоз-индуцирующие средства для лечения рака и иммунных и аутоиммунных заболеваний
CA2552050A1 (en) Substituted heterocycles and the uses thereof
RU2011115111A (ru) Замещенные пирролидин-2-карбоксамиды
JP2012519179A5 (https=)
RU2005122447A (ru) Энантиомеры производных тиофенгидроксамовой кислоты и их применение в качестве ингибиторов гдац
JP2006504656A5 (https=)
RU2011141188A (ru) Замещенные 2-меркаптохинолин-3-карбоксамиды в качестве kcnq2/3 модуляторов
RU2008112221A (ru) Соединения ряда изоиндолимидов, их композиции и способы применения
HRP20130865T1 (hr) Derivati pirazol piridina kao inhibitori nadph oksidaze
RU2006101541A (ru) Производные пиперазина и способ их применения